NeuMoDx Molecular Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
175
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$248M
NeuMoDx Molecular General Information
Description
Operator of a healthcare technology platform intended to offer molecular diagnostic testing tools. The company's platform offers in-vitro molecule testing facilities in hospitals and clinical reference laboratories, enabling laboratory professionals to operate more efficiently and cost-effectively, and increasing the use of molecular diagnostic testing by medical providers to better identify and treat disease early.
Contact Information
Website
www.neumodx.comCorporate Office
- 1250 Eisenhower Place
- Ann Arbor, MI 48108
- United States
Corporate Office
- 1250 Eisenhower Place
- Ann Arbor, MI 48108
- United States
NeuMoDx Molecular Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 17-Sep-2020 | $248M | Completed | Generating Revenue | ||
| 10. Debt - General | 31-Dec-2019 | Completed | Generating Revenue | |||
| 9. Debt - General | 30-Sep-2019 | Completed | Generating Revenue | |||
| 8. Debt - General | 01-Apr-2019 | Completed | Generating Revenue | |||
| 7. Debt - General | 30-Sep-2018 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 27-Apr-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 01-Jan-2018 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 29-Apr-2016 | Completed | Startup | |||
| 3. Early Stage VC (Series B) | 16-Jun-2015 | $26.1M | Completed | Startup | ||
| 2. Early Stage VC (Series B) | 01-Apr-2014 | $21.1M | $26.1M | Completed | Startup |
NeuMoDx Molecular Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series Q1 | ||||||||
| Series Q | ||||||||
| Series B | 5,936,420 | $0.000100 | 8% | $3.55 | $3.55 | 1x | $3.55 | 34.5% |
| Series A | 3,202,869 | $0.000100 | 8% | $1.56 | $1.56 | 1x | $1.56 | 18.61% |
NeuMoDx Molecular Comparisons
Industry
Financing
Details
NeuMoDx Molecular Competitors (48)
One of NeuMoDx Molecular’s 48 competitors is QuantuMDx, a Venture Capital-Backed company based in Newcastle Upon Tyne, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| QuantuMDx | Venture Capital-Backed | Newcastle Upon Tyne, United Kingdom | ||||
| ChipCare | Formerly VC-backed | Toronto, Canada | ||||
| Q-linea | Formerly VC-backed | Uppsala, Sweden | ||||
| Rheonix | Venture Capital-Backed | Ithaca, NY | ||||
| Biocartis | Venture Capital-Backed | Mechelen, Belgium |
NeuMoDx Molecular Patents
NeuMoDx Molecular Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3122903-A1 | System and method for processing biological samples | Active | 28-Mar-2014 | ||
| EP-3122903-A4 | System and method for processing biological samples | Active | 28-Mar-2014 | ||
| WO-2015149057-A1 | System and method for processing biological samples | Inactive | 28-Mar-2014 | ||
| ES-2805541-T3 | System and procedure for processing biological samples | Active | 28-Mar-2014 | ||
| EP-3122903-B1 | System for processing biological samples | Inactive | 28-Mar-2014 | C12Q1/6806 |
NeuMoDx Molecular Signals
NeuMoDx Molecular Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arboretum Ventures | Venture Capital | Minority | ||
| Baird Capital | PE/Buyout | Minority | ||
| Clarevia Ventures | Venture Capital | Minority | ||
| Pfizer Ventures | Corporate Venture Capital | Minority | ||
| University of Michigan Endowment | Limited Partner | Minority |
NeuMoDx Molecular FAQs
-
When was NeuMoDx Molecular founded?
NeuMoDx Molecular was founded in 2012.
-
Where is NeuMoDx Molecular headquartered?
NeuMoDx Molecular is headquartered in Ann Arbor, MI.
-
What is the size of NeuMoDx Molecular?
NeuMoDx Molecular has 175 total employees.
-
What industry is NeuMoDx Molecular in?
NeuMoDx Molecular’s primary industry is Diagnostic Equipment.
-
Is NeuMoDx Molecular a private or public company?
NeuMoDx Molecular is a Private company.
-
What is the current valuation of NeuMoDx Molecular?
The current valuation of NeuMoDx Molecular is .
-
What is NeuMoDx Molecular’s current revenue?
The current revenue for NeuMoDx Molecular is .
-
How much funding has NeuMoDx Molecular raised over time?
NeuMoDx Molecular has raised $85.6M.
-
Who are NeuMoDx Molecular’s investors?
Arboretum Ventures, Baird Capital, Clarevia Ventures, Pfizer Ventures, and University of Michigan Endowment have invested in NeuMoDx Molecular.
-
Who are NeuMoDx Molecular’s competitors?
QuantuMDx, ChipCare, Q-linea, Rheonix, and Biocartis are some of the 48 competitors of NeuMoDx Molecular.
-
When was NeuMoDx Molecular acquired?
NeuMoDx Molecular was acquired on 17-Sep-2020.
-
Who acquired NeuMoDx Molecular?
NeuMoDx Molecular was acquired by Qiagen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process